CAMBRIDGE, Mass.--(BUSINESS WIRE)--PERCIVIA LLC, (“PERCIVIA”) named Dr. Michael Wyand the Vice President of Global Operations and Nicholas Plumeridge the Vice President of Global Business Development. PERCIVIA is a venture formed by Crucell N.V. and Royal DSM N.V., to develop recombinant therapeutic proteins using the PER.C6® human cell line, with a focus on bio-similar monoclonal antibodies globally. Additionally, PERCIVIA outlicenses the PER.C6®cell line and provides logistical support by training and advising on the methods of recombinant protein production using the technology provided to licensees.
